149 related articles for article (PubMed ID: 38575671)
41. Novel pyrrolobenzodiazepine benzofused hybrid molecules inhibit NF-κB activity and synergise with bortezomib and ibrutinib in hematological cancers.
Lewis T; Corcoran DB; Thurston DE; Giles PJ; Ashelford K; Walsby EJ; Fegan CD; Pepper AGS; Miraz Rahman K; Pepper C
Haematologica; 2021 Apr; 106(4):958-967. PubMed ID: 32381576
[TBL] [Abstract][Full Text] [Related]
42. Targeting inhibitor of apoptosis proteins by Smac mimetic elicits cell death in poor prognostic subgroups of chronic lymphocytic leukemia.
Opel D; Schnaiter A; Dodier D; Jovanovic M; Gerhardinger A; Idler I; Mertens D; Bullinger L; Stilgenbauer S; Fulda S
Int J Cancer; 2015 Dec; 137(12):2959-70. PubMed ID: 26096065
[TBL] [Abstract][Full Text] [Related]
43. Development and characterization of prototypes for in vitro and in vivo mouse models of ibrutinib-resistant CLL.
Aslan B; Kismali G; Chen LS; Iles LR; Mahendra M; Peoples M; Gagea M; Fowlkes NW; Zheng X; Wang J; Vellano CP; Marszalek JR; Bertilaccio MTS; Gandhi V
Blood Adv; 2021 Aug; 5(16):3134-3146. PubMed ID: 34424317
[TBL] [Abstract][Full Text] [Related]
44. Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia.
Manna A; Aulakh S; Jani P; Ahmed S; Akhtar S; Coignet M; Heckman M; Meghji Z; Bhatia K; Sharma A; Sher T; Alegria V; Malavasi F; Chini EN; Chanan-Khan A; Ailawadhi S; Paulus A
Clin Cancer Res; 2019 Jul; 25(13):3974-3985. PubMed ID: 30940652
[TBL] [Abstract][Full Text] [Related]
45. The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia.
Herman SEM; Montraveta A; Niemann CU; Mora-Jensen H; Gulrajani M; Krantz F; Mantel R; Smith LL; McClanahan F; Harrington BK; Colomer D; Covey T; Byrd JC; Izumi R; Kaptein A; Ulrich R; Johnson AJ; Lannutti BJ; Wiestner A; Woyach JA
Clin Cancer Res; 2017 Jun; 23(11):2831-2841. PubMed ID: 27903679
[No Abstract] [Full Text] [Related]
46. Activation of the B-cell receptor successively activates NF-κB and STAT3 in chronic lymphocytic leukemia cells.
Rozovski U; Harris DM; Li P; Liu Z; Jain P; Veletic I; Ferrajoli A; Burger J; Thompson P; Jain N; Wierda W; Keating MJ; Estrov Z
Int J Cancer; 2017 Nov; 141(10):2076-2081. PubMed ID: 28722170
[TBL] [Abstract][Full Text] [Related]
47. NF-kappaB as a therapeutic target in chronic lymphocytic leukemia.
Lopez-Guerra M; Colomer D
Expert Opin Ther Targets; 2010 Mar; 14(3):275-88. PubMed ID: 20148715
[TBL] [Abstract][Full Text] [Related]
48. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
Herman SE; Gordon AL; Hertlein E; Ramanunni A; Zhang X; Jaglowski S; Flynn J; Jones J; Blum KA; Buggy JJ; Hamdy A; Johnson AJ; Byrd JC
Blood; 2011 Jun; 117(23):6287-96. PubMed ID: 21422473
[TBL] [Abstract][Full Text] [Related]
49. Cytokine modulation of nuclear factor-kappaB activity in B-chronic lymphocytic leukemia.
Zaninoni A; Imperiali FG; Pasquini C; Zanella A; Barcellini W
Exp Hematol; 2003 Mar; 31(3):185-90. PubMed ID: 12644014
[TBL] [Abstract][Full Text] [Related]
50. The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-κB response in chronic lymphocytic leukemia cells.
Gupta SV; Hertlein E; Lu Y; Sass EJ; Lapalombella R; Chen TL; Davis ME; Woyach JA; Lehman A; Jarjoura D; Byrd JC; Lucas DM
Clin Cancer Res; 2013 May; 19(9):2406-19. PubMed ID: 23515408
[TBL] [Abstract][Full Text] [Related]
51. Tumor necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukemia: analysis of NF-kappa B/Rel-regulated inhibitors of apoptosis.
Munzert G; Kirchner D; Stobbe H; Bergmann L; Schmid RM; Döhner H; Heimpel H
Blood; 2002 Nov; 100(10):3749-56. PubMed ID: 12411322
[TBL] [Abstract][Full Text] [Related]
52. MARCKS affects cell motility and response to BTK inhibitors in CLL.
Beckmann L; Berg V; Dickhut C; Sun C; Merkel O; Bloehdorn J; Robrecht S; Seifert M; da Palma Guerreiro A; Claasen J; Loroch S; Oliverio M; Underbayev C; Vaughn L; Thomalla D; Hülsemann MF; Tausch E; Fischer K; Fink AM; Eichhorst B; Sickmann A; Wendtner CM; Stilgenbauer S; Hallek M; Wiestner A; Zahedi RP; Frenzel LP
Blood; 2021 Aug; 138(7):544-556. PubMed ID: 33735912
[TBL] [Abstract][Full Text] [Related]
53. Increased autocrine interleukin-6 production is significantly associated with worse clinical outcome in patients with chronic lymphocytic leukemia.
Wang HQ; Jia L; Li YT; Farren T; Agrawal SG; Liu FT
J Cell Physiol; 2019 Aug; 234(8):13994-14006. PubMed ID: 30623437
[TBL] [Abstract][Full Text] [Related]
54. UGT2B17 modifies drug response in chronic lymphocytic leukaemia.
Allain EP; Rouleau M; Vanura K; Tremblay S; Vaillancourt J; Bat V; Caron P; Villeneuve L; Labriet A; Turcotte V; Le T; Shehata M; Schnabl S; Demirtas D; Hubmann R; Joly-Beauparlant C; Droit A; Jäger U; Staber PB; Lévesque E; Guillemette C
Br J Cancer; 2020 Jul; 123(2):240-251. PubMed ID: 32418995
[TBL] [Abstract][Full Text] [Related]
55. Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells.
Patel V; Balakrishnan K; Bibikova E; Ayres M; Keating MJ; Wierda WG; Gandhi V
Clin Cancer Res; 2017 Jul; 23(14):3734-3743. PubMed ID: 28034907
[No Abstract] [Full Text] [Related]
56. Targeting neddylation effectively antagonizes nuclear factor-κB in chronic lymphocytic leukemia B-cells.
Godbersen JC; Paiva C; Danilova OV; Berger A; Brown JR; Danilov AV
Leuk Lymphoma; 2015 May; 56(5):1566-9. PubMed ID: 26086969
[TBL] [Abstract][Full Text] [Related]
57. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).
Woyach JA; Bojnik E; Ruppert AS; Stefanovski MR; Goettl VM; Smucker KA; Smith LL; Dubovsky JA; Towns WH; MacMurray J; Harrington BK; Davis ME; Gobessi S; Laurenti L; Chang BY; Buggy JJ; Efremov DG; Byrd JC; Johnson AJ
Blood; 2014 Feb; 123(8):1207-13. PubMed ID: 24311722
[TBL] [Abstract][Full Text] [Related]
58. Activation of Protein Tyrosine Phosphatase Receptor Type γ Suppresses Mechanisms of Adhesion and Survival in Chronic Lymphocytic Leukemia Cells.
Montresor A; Toffali L; Fumagalli L; Constantin G; Rigo A; Ferrarini I; Vinante F; Laudanna C
J Immunol; 2021 Jul; 207(2):671-684. PubMed ID: 34162728
[TBL] [Abstract][Full Text] [Related]
59. Interaction with vascular endothelium enhances survival in primary chronic lymphocytic leukemia cells via NF-kappaB activation and de novo gene transcription.
Buggins AG; Pepper C; Patten PE; Hewamana S; Gohil S; Moorhead J; Folarin N; Yallop D; Thomas NS; Mufti GJ; Fegan C; Devereux S
Cancer Res; 2010 Oct; 70(19):7523-33. PubMed ID: 20736369
[TBL] [Abstract][Full Text] [Related]
60. Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib.
Guo A; Lu P; Galanina N; Nabhan C; Smith SM; Coleman M; Wang YL
Oncotarget; 2016 Jan; 7(4):4598-610. PubMed ID: 26717038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
